Annual CFO
-$117.35 M
+$111.46 M+48.71%
December 31, 2023
Summary
- As of February 7, 2025, MCRB annual cash flow from operations is -$117.35 million, with the most recent change of +$111.46 million (+48.71%) on December 31, 2023.
- During the last 3 years, MCRB annual CFO has fallen by -$23.74 million (-25.36%).
- MCRB annual CFO is now -367.19% below its all-time high of $43.92 million, reached on December 31, 2016.
Performance
MCRB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$34.68 M
+$5.13 M+12.89%
September 30, 2024
Summary
- As of February 7, 2025, MCRB quarterly cash flow from operations is -$34.68 million, with the most recent change of +$5.13 million (+12.89%) on September 30, 2024.
- Over the past year, MCRB quarterly CFO has increased by +$12.82 million (+26.99%).
- MCRB quarterly CFO is now -127.15% below its all-time high of $127.74 million, reached on September 30, 2021.
Performance
MCRB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$157.23 M
+$24.57 M+13.52%
September 30, 2024
Summary
- As of February 7, 2025, MCRB TTM cash flow from operations is -$157.23 million, with the most recent change of +$24.57 million (+13.52%) on September 30, 2024.
- Over the past year, MCRB TTM CFO has dropped by -$39.87 million (-33.98%).
- MCRB TTM CFO is now -328.16% below its all-time high of $68.91 million, reached on March 31, 2016.
Performance
MCRB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
MCRB Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +48.7% | +27.0% | -34.0% |
| 3 y3 years | -25.4% | +34.4% | +31.3% |
| 5 y5 years | -86.7% | +34.4% | +31.3% |
MCRB Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1854.7% | +48.7% | -152.6% | +54.7% | -2450.9% | +34.2% |
| 5 y | 5-year | -1854.7% | +48.7% | -127.2% | +54.7% | -487.0% | +34.2% |
| alltime | all time | -367.2% | +48.7% | -127.2% | +54.7% | -328.2% | +34.2% |
Seres Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$34.68 M(-12.9%) | -$157.23 M(-13.5%) |
| Jun 2024 | - | -$39.81 M(+13.0%) | -$181.80 M(+139.2%) |
| Mar 2024 | - | -$35.24 M(-25.8%) | -$76.01 M(-35.2%) |
| Dec 2023 | -$117.35 M(-48.7%) | -$47.50 M(-19.8%) | -$117.35 M(-4.4%) |
| Sep 2023 | - | -$59.26 M(-189.8%) | -$122.75 M(-0.3%) |
| Jun 2023 | - | $65.98 M(-186.2%) | -$123.07 M(-48.5%) |
| Mar 2023 | - | -$76.58 M(+44.8%) | -$238.96 M(+4.4%) |
| Dec 2022 | -$228.82 M(-3521.3%) | -$52.89 M(-11.2%) | -$228.82 M(+0.5%) |
| Sep 2022 | - | -$59.58 M(+19.4%) | -$227.79 M(+463.0%) |
| Jun 2022 | - | -$49.90 M(-24.9%) | -$40.46 M(+33.7%) |
| Mar 2022 | - | -$66.44 M(+28.1%) | -$30.26 M(-552.5%) |
| Dec 2021 | $6.69 M(-107.1%) | -$51.86 M(-140.6%) | $6.69 M(-83.5%) |
| Sep 2021 | - | $127.74 M(-421.8%) | $40.62 M(-136.0%) |
| Jun 2021 | - | -$39.70 M(+34.6%) | -$112.98 M(+14.3%) |
| Mar 2021 | - | -$29.50 M(+64.5%) | -$98.86 M(+5.6%) |
| Dec 2020 | -$93.61 M(+22.3%) | -$17.93 M(-30.7%) | -$93.61 M(+4.3%) |
| Sep 2020 | - | -$25.87 M(+1.2%) | -$89.73 M(+9.2%) |
| Jun 2020 | - | -$25.57 M(+5.4%) | -$82.16 M(+20.1%) |
| Mar 2020 | - | -$24.25 M(+72.6%) | -$68.38 M(-10.6%) |
| Dec 2019 | -$76.52 M | -$14.05 M(-23.2%) | -$76.52 M(+53.6%) |
| Sep 2019 | - | -$18.29 M(+55.2%) | -$49.81 M(-8.8%) |
| Jun 2019 | - | -$11.79 M(-63.6%) | -$54.60 M(-20.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$32.39 M(-355.7%) | -$68.48 M(+9.0%) |
| Dec 2018 | -$62.85 M(-16.8%) | $12.67 M(-154.9%) | -$62.85 M(-34.6%) |
| Sep 2018 | - | -$23.08 M(-10.1%) | -$96.13 M(+25.4%) |
| Jun 2018 | - | -$25.67 M(-4.1%) | -$76.66 M(+0.0%) |
| Mar 2018 | - | -$26.76 M(+29.9%) | -$76.64 M(+1.5%) |
| Dec 2017 | -$75.52 M(-272.0%) | -$20.61 M(+470.9%) | -$75.52 M(-0.3%) |
| Sep 2017 | - | -$3.61 M(-85.9%) | -$75.72 M(-9.3%) |
| Jun 2017 | - | -$25.66 M(+0.0%) | -$83.48 M(+0.4%) |
| Mar 2017 | - | -$25.65 M(+23.3%) | -$83.14 M(-289.3%) |
| Dec 2016 | $43.92 M(-207.5%) | -$20.80 M(+83.0%) | $43.92 M(-17.4%) |
| Sep 2016 | - | -$11.37 M(-55.1%) | $53.16 M(-0.2%) |
| Jun 2016 | - | -$25.32 M(-125.0%) | $53.24 M(-22.7%) |
| Mar 2016 | - | $101.42 M(-976.6%) | $68.91 M(-268.7%) |
| Dec 2015 | -$40.84 M(+294.3%) | -$11.57 M(+2.6%) | -$40.84 M(+22.3%) |
| Sep 2015 | - | -$11.28 M(+16.8%) | -$33.39 M(+34.3%) |
| Jun 2015 | - | -$9.66 M(+15.8%) | -$24.86 M(+43.9%) |
| Mar 2015 | - | -$8.34 M(+102.7%) | -$17.27 M(+66.8%) |
| Dec 2014 | -$10.36 M(+94.7%) | -$4.12 M(+50.0%) | -$10.36 M(+65.9%) |
| Sep 2014 | - | -$2.74 M(+32.2%) | -$6.24 M(+78.4%) |
| Jun 2014 | - | -$2.08 M(+45.9%) | -$3.50 M(+145.9%) |
| Mar 2014 | - | -$1.42 M | -$1.42 M |
| Dec 2013 | -$5.32 M(+81.9%) | - | - |
| Dec 2012 | -$2.92 M | - | - |
FAQ
- What is Seres Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Seres Therapeutics?
- What is Seres Therapeutics annual CFO year-on-year change?
- What is Seres Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Seres Therapeutics?
- What is Seres Therapeutics quarterly CFO year-on-year change?
- What is Seres Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Seres Therapeutics?
- What is Seres Therapeutics TTM CFO year-on-year change?
What is Seres Therapeutics annual cash flow from operations?
The current annual CFO of MCRB is -$117.35 M
What is the all time high annual CFO for Seres Therapeutics?
Seres Therapeutics all-time high annual cash flow from operations is $43.92 M
What is Seres Therapeutics annual CFO year-on-year change?
Over the past year, MCRB annual cash flow from operations has changed by +$111.46 M (+48.71%)
What is Seres Therapeutics quarterly cash flow from operations?
The current quarterly CFO of MCRB is -$34.68 M
What is the all time high quarterly CFO for Seres Therapeutics?
Seres Therapeutics all-time high quarterly cash flow from operations is $127.74 M
What is Seres Therapeutics quarterly CFO year-on-year change?
Over the past year, MCRB quarterly cash flow from operations has changed by +$12.82 M (+26.99%)
What is Seres Therapeutics TTM cash flow from operations?
The current TTM CFO of MCRB is -$157.23 M
What is the all time high TTM CFO for Seres Therapeutics?
Seres Therapeutics all-time high TTM cash flow from operations is $68.91 M
What is Seres Therapeutics TTM CFO year-on-year change?
Over the past year, MCRB TTM cash flow from operations has changed by -$39.87 M (-33.98%)